Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
SLDB Solid Biosciences	$2.62 -6.0%	$3.68	$2.45 ▼ $10.46	$205.77M	2.32	1.02 million shs	450,107 shs
SNDL SNDL	$1.31 -1.1%	$1.43	$1.26 ▼ $2.93	$342.92M	3.68	2.23 million shs	205,545 shs
TCRX TScan Therapeutics	$1.27 -4.5%	$1.47	$1.02 ▼ $9.69	$72.15M	1.06	361,221 shs	21,409 shs
TRDA Entrada Therapeutics	$8.48 -2.5%	$9.13	$7.10 ▼ $21.79	$322.22M	0.04	128,221 shs	18,873 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
SLDB Solid Biosciences	-3.79%	-17.21%	+3.33%	-20.96%	-71.38%
SNDL SNDL	0.00%	+0.76%	-2.94%	-27.47%	-45.00%
TCRX TScan Therapeutics	-2.92%	-2.21%	+7.26%	-36.97%	-83.40%
TRDA Entrada Therapeutics	-1.36%	+4.44%	+10.13%	-31.44%	-38.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
SLDB Solid Biosciences	3.9859 of 5 stars	3.7	4.0	3.8	3.3	1.3
SNDL SNDL	3.0667 of 5 stars	3.5	3.0	2.7	0.0	1.3
TCRX TScan Therapeutics	3.4116 of 5 stars	4.5	4.0	1.8	1.7	0.6
TRDA Entrada Therapeutics	3.0534 of 5 stars	3.6	3.0	2.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
SLDB Solid Biosciences	3.33	Buy	$15.67	497.28% Upside
SNDL SNDL	3.00	Buy	$3.63	177.78% Upside
TCRX TScan Therapeutics	3.00	Buy	$8.50	569.29% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	202.57% Upside

Current Analyst Ratings Breakdown

Latest TCRX, SNDL, TRDA, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00
4/8/2025	TCRX TScan Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/31/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
3/19/2025	SNDL SNDL	ATB Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target		$3.50 ➝ $4.00
3/14/2025	TCRX TScan Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$10.00
3/13/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $11.00
3/10/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $20.00
3/7/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/7/2025	TCRX TScan Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$14.00 ➝ $3.00
3/6/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00

(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
SLDB Solid Biosciences	$8.09M	25.13	N/A	N/A	$6.27 per share	0.42
SNDL SNDL	$927.61M	0.37	N/A	N/A	$3.47 per share	0.38
TCRX TScan Therapeutics	$4.42M	16.26	N/A	N/A	$3.15 per share	0.40
TRDA Entrada Therapeutics	$172.22M	1.87	N/A	N/A	$7.26 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
SLDB Solid Biosciences	-$96.01M	-$3.04	N/A	N/A	N/A	N/A	-58.75%	-47.84%	5/21/2025 (Estimated)
SNDL SNDL	-$127.91M	-$0.29	N/A	N/A	N/A	-12.11%	-8.27%	-6.96%	N/A
TCRX TScan Therapeutics	-$89.22M	-$1.09	N/A	N/A	N/A	-1,188.88%	-58.72%	-36.02%	N/A
TRDA Entrada Therapeutics	-$6.68M	$0.81	5.34	N/A	N/A	25.53%	16.11%	10.39%	N/A

Latest TCRX, SNDL, TRDA, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/8/2025	Q1 2025	TRDA Entrada Therapeutics	-$0.78	-$0.42	+$0.36	-$0.42	$10.98 million	$8.75 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million
3/18/2025	Q4 2024	SNDL SNDL	-$0.01	-$0.19	-$0.18	-$0.19	$248.10 million	$179.06 million
3/5/2025	Q4 2024	TCRX TScan Therapeutics	-$0.27	-$0.29	-$0.02	-$0.30	$1.43 million	$0.67 million
2/27/2025	Q4 2024	TRDA Entrada Therapeutics	-$0.66	$0.03	+$0.69	$0.03	$11.95 million	$12.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
SLDB Solid Biosciences	N/A	7.85	7.85
SNDL SNDL	0.10	5.61	4.16
TCRX TScan Therapeutics	0.13	9.56	9.56
TRDA Entrada Therapeutics	N/A	6.59	6.59

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
SLDB Solid Biosciences	81.46%
SNDL SNDL	N/A
TCRX TScan Therapeutics	82.83%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
SLDB Solid Biosciences	1.90%
SNDL SNDL	N/A
TCRX TScan Therapeutics	2.76%
TRDA Entrada Therapeutics	8.11%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
SLDB Solid Biosciences	100	77.50 million	35.05 million	Optionable
SNDL SNDL	580	262.78 million	N/A	Optionable
TCRX TScan Therapeutics	100	56.59 million	51.90 million	Not Optionable
TRDA Entrada Therapeutics	110	37.95 million	34.58 million	Optionable

TCRX, SNDL, TRDA, and SLDB Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

May 12 at 5:45 PM | marketbeat.com

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

May 11 at 5:14 PM | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

May 8, 2025 | zacks.com

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Projected to Post Earnings on Tuesday

May 5, 2025 | americanbankingnews.com

Entrada Trims Workforce by 20 Percent to Focus on Advancing DMD, Other Candidates

May 2, 2025 | precisionmedicineonline.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Price T Rowe Associates Inc. MD

May 2, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

May 1, 2025 | marketbeat.com

Entrada Cuts 20% of Workforce, Targeting Research Employees

April 30, 2025 | biospace.com

Entrada lays off 20% of staff weeks after having FDA hold lifted

April 30, 2025 | fiercebiotech.com

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

April 29, 2025 | zacks.com

Renaissance Technologies LLC Acquires 72,400 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 27, 2025 | marketbeat.com

Vanguard Group Inc. Has $25.32 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

April 17, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.

April 16, 2025 | marketbeat.com

Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMD

March 26, 2025 | nasdaq.com

Entrada receives authorization in the UK to initiate ELEVATE-45-201 study

March 25, 2025 | markets.businessinsider.com

Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK

March 24, 2025 | msn.com

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

March 24, 2025 | globenewswire.com

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

March 3, 2025 | finance.yahoo.com

Entrada Therapeutics price target lowered to $23 from $29 at Roth MKM

March 1, 2025 | markets.businessinsider.com

Oppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)

February 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, SNDL, TRDA, and SLDB Company Descriptions

Solid Biosciences NASDAQ:SLDB

$2.62 -0.17 (-5.99%)

As of 10:52 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

SNDL NASDAQ:SNDL

$1.30 -0.02 (-1.14%)

As of 10:51 AM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

TScan Therapeutics NASDAQ:TCRX

$1.27 -0.06 (-4.51%)

As of 10:50 AM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Entrada Therapeutics NASDAQ:TRDA

$8.48 -0.22 (-2.49%)

As of 10:52 AM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time